Peru suspends trial of China’s Sinopharm Covid-19 vaccine after ‘serious adverse event’



[ad_1]

LIMA (REUTERS) – Peru suspended trials of the Chinese Sinopharm Covid-19 vaccine due to a “serious adverse event” that occurred with one of the study volunteers, the Peruvian government said in a statement on Saturday (December 12).

The Health Ministry said the event is “under investigation to determine if it is related to the vaccine or if there is another explanation.”

Sinopharm Group, which is conducting its trials in Peru with some 12,000 volunteers, was about to complete the first stage of trials in the next few days.

Some 36,544 people have died so far in Peru from the coronavirus pandemic.

“The decision to temporarily suspend clinical trials is a safety measure contemplated in the regulations for clinical trials and protocols established to protect the health of research subjects, the Ministry of Health said in the statement.

German Malaga, chief researcher at the local Cayetano Heredia University, involved in the study, said a volunteer had experienced decreased strength in his legs, among other symptoms.



[ad_2]